Study period 1 | Study period 2 | |||
---|---|---|---|---|
FBG (mg/dL) | Test (mean ± SEM) | Control (mean ± SEM) | ||
0 week | 12 weeks | 14 weeks | 26 weeks | |
Group 1a | 174 ± 14 | 160 ± 10 | 199 ± 15 | 192 ± 19 |
Control (mean ± SEM) | Test (mean ± SEM) | |||
0 week | 12 weeks | 14 weeks | 26 weeks | |
Group 2b | 166 ± 11 | 171 ± 9 | 183 ± 13 | 160 ± 7 |
HbA1c (%) | Test (mean ± SEM) | Control (mean ± SEM) | ||
0 week | 12 weeks | 14 weeks | 26 weeks | |
Group 1a | 7.9 ± 0.46 | 6.5 ± 0.30a | 6.5 ± 0.30 | 7.1 ± 0.39 |
Control (mean ± SEM) | Test (mean ± SEM) | |||
0 week | 12 weeks | 14 weeks | 26 weeks | |
Group 2b | 7.6 ± 0.36 | 7.0 ± 0.31 | 7.0 ± 0.31 | 6.7 ± 0.24 |
Insulin (IU/L) | Test (mean ± SEM) | Control (mean ± SEM) | ||
0 week | 12 weeks | 14 weeks | 26 weeks | |
Group 1a | 12.2 ± 10.4 | 14.9 ± 8.0 | 14.9 ± 8.0 | 12.1 ± 10.0 |
Control (mean ± SEM) | Test (mean ± SEM) | |||
0 week | 12 weeks | 14 weeks | 26 weeks | |
Group 2b | 16.6 ± 3.5 | 12.3 ± 1.5 | 12.3 ± 1.5 | 10.4 ± 1.2 |